

Name of Journal: *World Journal of Gastrointestinal Pharmacology and Therapeutics*

ESPS Manuscript NO: 18368


Manuscript Type: Original Article

*Basic study*

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis

*Institutional animal care and use committee statement:* Assessment of plecanatide in DSS and TNBS murine IBD models was conducted by Epistem Ltd, Manchester, UK under License 40/2364. Studies to determine the efficacy of dolcanatide in an acute DSS-induced colitis model of IBD was also performed at Epistem Ltd, Manchester, UK under License 40/3033

The preliminary animal studies employing BALB/c and TCR $\alpha^{-/-}$  mice were performed under the direct supervision of Doctor Scott Plevy at the University of Pittsburgh School of Medicine (Pittsburg, PA). All technical procedures, animal housing, diet, water, environmental conditions and other procedures will be performed as described in the *Guide for the Care and Use of Laboratory Animals*, NRC, 1996, and in accordance with the animal protocol approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh.



Kunwar Shailubhai

Correspondence to: Kunwar Shailubhai, Doctor of Philosophy, Chief Scientific Officer, R and D Center, Synergy Pharmaceuticals Inc., 3805 Old Easton Road, Doylestown, PA 18902, United States.  
[shailu@synergypharma.com](mailto:shailu@synergypharma.com)